Fig. 6

Lucidadiol modulates the Akt/MAPK signaling pathway in B16 melanoma cells. A Representative blot of p-Akt and p-MAPK in B16 melanoma cells treated with lucidadiol at 0 and 15 µM for 0 and 48 h. B Statistical analyses of phosphorylated Akt, ERK, JNK, and p38 expression levels with/without lucidadiol treatment are represented in the graphs. The data are presented as the mean ± SD. *p < 0.05 when compared with the control group